What is Rein Therapeutics Inc?
, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 47.63M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.